Xeris Biopharma Holdings, Inc. (XERS)Healthcare | Biotechnology | Chicago, United States | NasdaqGS
6.37 USD
+0.25
(4.085%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.33 -0.04 (-0.038%) ⇩ (April 17, 2026, 5:48 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:55 p.m. EDT
XERS appears to be a stock with high risk due to its overall risk rating of 7 and a low dividend yield. The recent price history shows volatility, with the stock trading near its 52-week low. While the stock has a moderate buy recommendation, the fundamentals are weak, with a high debt-to-equity ratio and low profit margins. The options data suggests cautious sentiment, with mixed signals between bullish and bearish positions. Short-term traders may consider buying calls if there is a potential for a rebound, but long-term investors should be cautious due to the company's financial structure and uncertain future prospects. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.190532 |
| MSTL | 0.198936 |
| AutoTheta | 0.237846 |
| AutoARIMA | 0.261237 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 10.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.188 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1885.441 |
| Revenue per Share | 1.819 |
| Market Cap | 1,098,387,328 |
| Trailing P/E | Infinity |
| Forward P/E | 17.19 |
| Beta | 0.99 |
| Profit Margins | 0.19% |
| Previous Name | Xeris Pharmaceuticals, Inc. |
| Website | https://www.xerispharma.com |
As of April 11, 2026, 2:55 p.m. EDT: Options speculators are showing mixed signals. For calls, there is significant positioning in out-of-the-money (OTM) strikes, particularly for higher strike prices, which may indicate bullish sentiment. However, the ATM strikes are showing lower volume and open interest, suggesting uncertainty. Puts show similar patterns, with OTM strikes having higher open interest, which could indicate caution or hedging. The IV (implied volatility) is generally low, suggesting limited expectations for large price swings in the near term. Overall, the options data suggests a cautious outlook with some potential for upward movement, but not strong enough to signal a clear trend.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5223881 |
| Address1 | 1,375 West Fulton Street |
| Address2 | Suite 1300 |
| All Time High | 27.98 |
| All Time Low | 0.97 |
| Ask | 6.44 |
| Ask Size | 13 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 1,358,860 |
| Average Daily Volume3 Month | 1,805,034 |
| Average Volume | 1,805,034 |
| Average Volume10Days | 1,358,860 |
| Beta | 0.987 |
| Bid | 6.23 |
| Bid Size | 13 |
| Board Risk | 7 |
| Book Value | 0.082 |
| City | Chicago |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.37 |
| Current Ratio | 2.193 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.4099 |
| Day Low | 6.165 |
| Debt To Equity | 1,885.441 |
| Display Name | Xeris Biopharma |
| Earnings Call Timestamp End | 1,772,458,200 |
| Earnings Call Timestamp Start | 1,772,458,200 |
| Earnings Timestamp | 1,772,458,200 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | 37,052,000 |
| Ebitda Margins | 0.12696 |
| Enterprise To Ebitda | 33.613 |
| Enterprise To Revenue | 4.267 |
| Enterprise Value | 1,245,443,328 |
| Eps Current Year | 0.14225 |
| Eps Forward | 0.3705 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.1222 |
| Fifty Day Average Change | 0.24779987 |
| Fifty Day Average Change Percent | 0.040475626 |
| Fifty Two Week Change Percent | 52.23881 |
| Fifty Two Week High | 10.08 |
| Fifty Two Week High Change | -3.71 |
| Fifty Two Week High Change Percent | -0.36805555 |
| Fifty Two Week Low | 3.95 |
| Fifty Two Week Low Change | 2.4199998 |
| Fifty Two Week Low Change Percent | 0.6126582 |
| Fifty Two Week Range | 3.95 - 10.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,587,800,000 |
| Float Shares | 163,613,154 |
| Forward Eps | 0.3705 |
| Forward P E | 17.192982 |
| Free Cashflow | 25,969,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 435 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.85414004 |
| Gross Profits | 249,276,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.037049998 |
| Held Percent Institutions | 0.59219 |
| Implied Shares Outstanding | 172,431,290 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. |
| Long Name | Xeris Biopharma Holdings, Inc. |
| Market | us_market |
| Market Cap | 1,098,387,328 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_105901792 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-16 |
| Net Income To Common | 554,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,097,525,160 |
| Number Of Analyst Opinions | 7 |
| Open | 6.26 |
| Operating Cashflow | 28,626,000 |
| Operating Margins | 0.19547 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 844 445 5704 |
| Post Market Change | -0.03789997 |
| Post Market Change Percent | -0.594976 |
| Post Market Price | 6.3321 |
| Post Market Time | 1,776,462,488 |
| Prev Name | Xeris Pharmaceuticals, Inc. |
| Previous Close | 6.12 |
| Price Eps Current Year | 44.780315 |
| Price Hint | 2 |
| Price To Book | 77.68292 |
| Price To Sales Trailing12 Months | 3.7635984 |
| Profit Margins | 0.0019 |
| Quick Ratio | 1.479 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.25 |
| Regular Market Change Percent | 4.08497 |
| Regular Market Day High | 6.4099 |
| Regular Market Day Low | 6.165 |
| Regular Market Day Range | 6.165 - 6.4099 |
| Regular Market Open | 6.26 |
| Regular Market Previous Close | 6.12 |
| Regular Market Price | 6.37 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,242,658 |
| Return On Assets | 0.04404 |
| Revenue Growth | 0.428 |
| Revenue Per Share | 1.819 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 172,431,290 |
| Shares Percent Shares Out | 0.0952 |
| Shares Short | 16,412,903 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 17,015,319 |
| Short Name | Xeris Biopharma Holdings, Inc. |
| Short Percent Of Float | 0.0988 |
| Short Ratio | 7.8 |
| Source Interval | 15 |
| State | IL |
| Symbol | XERS |
| Target High Price | 18.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 11.14286 |
| Target Median Price | 10.0 |
| Total Cash | 111,042,000 |
| Total Cash Per Share | 0.644 |
| Total Debt | 258,098,000 |
| Total Revenue | 291,844,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.9973 |
| Two Hundred Day Average Change | -0.62730026 |
| Two Hundred Day Average Change Percent | -0.0896489 |
| Type Disp | Equity |
| Volume | 1,242,658 |
| Website | https://www.xerispharma.com |
| Zip | 60,607 |